Richard L. Schilsky, MD | Authors

John F Vela, MD, Inc

71 SAINT FRANCIS AVE

Tiffin

44883

Articles

Targeted Therapy for Cancer: Asking the Right Questions

October 23, 2012

Our knowledge of how to best develop and use targeted therapies for cancer remains nascent, and optimizing the use of such treatments will likely require answering one other question that I have paraphrased from the Passover Haggadah: How is this tumor different from all other tumors?

Pharmacology and Clinical Status of Capecitabine

September 01, 2000

Capecitabine (Xeloda) is a new, orally administered, enzyme-activated fluoropyrimidine carbamate designed to generate high levels of fluorouracil (5-FU) in tumor cells. Selective tumor activation of 5´-deoxy-5-fluorouridine,

Pharmacology and Clinical Status of Capecitabine

September 01, 2000

Capecitabine (Xeloda) is a new, orally administered, enzyme-activated fluoropyrimidine carbamate designed to generate high levels of fluorouracil (5-FU) in tumor cells. Selective tumor activation of 5´-deoxy-5-fluorouridine,

Clinical Status and Optimal Use of Amifostine

January 01, 1999

An important, though as yet elusive, goal of cancer chemotherapy is the development of agents that are selectively toxic to tumor cells and, thus, permit effective cancer treatment to be administered without severe, often life-threatening toxicity to normal tissues. Until such agents are available, an alternative strategy to improve the therapeutic index of cancer chemotherapy is the administration of cytoprotective agents to selectively protect normal tissues from injury by cytotoxic drugs.

Recent Advances in Oral Fluoropyrimidine Therapies

October 01, 1998

Recent strategies to improve the outcome of fluoropyrimidine chemotherapy for patients with cancer have focused on better selection of patients likely to respond to such therapy and on protracted exposure to 5-fluorouracil (5-FU). Cellular

Biochemical and Clinical Pharmacology of 5-Fluorouracil

October 01, 1998

The cellular and clinical pharmacology of fluoropyrimidines is characterized by marked interpatient variability in tumor response and patient tolerance. Understanding the metabolic pathways followed by 5-fluorouracil (5-FU) has